Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature

<p>Showing serum pancreatic polypeptide (PP) levels (pg/mL) over time. Octreotide treatment was initiated in February 2014. Since initiation of octreotide treatment, the PP levels remain stable. Reference range PP (0.0-418.0 pg/mL).</p>

Case Reports in Gastrointestinal Medicine

fig1

Figure 1

Figure 1: Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature 

Figure 1 | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature 